Adobe patches a critical PDF flaw exploited for months, allowing attackers to bypass sandbox protections and deliver malware.

It's not clear how many people were compromised by this hacking campaign, but a security researcher said the hackers were ...

An attacker has been using maliciously crafted PDF files to exploit a zero-day in Adobe Acrobat and Reader for at least four ...

Want to correct errors or update content in a PDF? Whether you prefer a powerful, corporate-friendly solution or a basic app you can use at no cost, we're here to help you find the right PDF software ...

Eli Lilly's GLP-1 drugs have seen strong demand, which has investors excited about the future. The company knows that its GLP-1 success won't last forever and is exploring additional paths. Eli Lilly ...

Java ranked third in the Tiobe Index for January 2026 at 8.71%, holding steady behind Python and C and just ahead of C++. Tiobe named C# its Programming Language of the Year for 2025 after the largest ...

Artificial intelligence and its promise to revolutionize programming—and possibly overthrow human sovereignty—is a central story of the post-Covid world. But for JavaScript developers, it is only one ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Agent workflows make transport a first-order ...

Just describe your edits to ChatGPT, and the Photoshop, Acrobat, and Express apps will do it for you or surface the tool you need. Just describe your edits to ChatGPT, and the Photoshop, Acrobat, ...

For a decade after its discovery, CRISPR gene editing was stuck on the cusp of transforming medicine. Then, in 2023, scientists started using it on sickle-cell disease, and Victoria Gray, a patient ...

Consumers are far more open to gene-edited foods when the benefits are personal, values-driven and clearly explained, according to recent research from The Center for Food Integrity (CFI) and FMI – ...

Regeneron Pharmaceuticals is committing $150 million to begin an alliance on a Tessera Therapeutics gene-editing medicine nearing the clinic as a potential treatment for a rare disease that leads to ...